Abstract
In 2010, 217,730 men will have been diagnosed with prostate cancer (PCa) in the United States of America (USA), and around 32,730 will have died from the disease [1]. Depending on the extent of prostate-specific antigen (PSA) testing, similar ratios of incidence and mortality will be seen throughout Europe; PCa is the second commonest cause of death from cancer in men in the UK, and in the USA, it is estimated that a man aged 40 years has a 16 % chance of being diagnosed and a 3 % lifetime chance of dying from PCa [2]. Once diagnosed, the chance of a man dying from his cancer rather than other causes depends not only on the biological aggressiveness of the tumor and the age and comorbidity of the individual in question but crucially on the stage of the disease at diagnosis and, by definition, how early it has been detected. Screening for disease to allow early detection is now an integral part of modern medicine, and screening for breast, cervical, and colorectal cancer is now standard practice in some countries. Although PCa is an equally important health problem, PSA testing to screen for the disease, allowing earlier detection and thereby reducing the chance of a man dying from PCa, remains controversial with the medical community divided on whether this approach causes more harm than good.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.
Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2006. Bethesda: National Cancer Institute; 2009. Table 23.9 cancer of the prostate. Available at http://seer.cancer.gov/csr/1975_2006.
Wilson JM, Jungner YG. Principles and practice of screening for disease. WHO Chron. 1968;22(11):473.
Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232–41.
Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98.
Abrahamsson PA, Artibani W, Chapple CR, Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol. 2009;56(2):270–1.
Chan EC, Barry MJ, Vernon SW, Ahn C. Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey. J Gen Intern Med. 2006;21(3):257–9.
Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3):636–44.
Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94(1):51–6.
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med. 1991;324(17):1156–61.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.
Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917–29.
Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer. 2007;31(3):226–36.
Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484–9.
U.S. Preventative Services Task Force. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–91.
Schröder FH, Hugosson J, Roobol MJ, et al. Screening and Âprostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.
Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.
PCRMP Guide No 2: information for primary care. PSA testing in asymptomatic men. 2010. http://www.cancerscreening.nhs.uk/prostate/pcrmp02/pdf
Okotie OT, Roehl KA, Han M, et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70(6):1117–20.
Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14–23.
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860–4.
Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273(4):289–94.
Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97(15):1132–7.
Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ. 2009;339:b3537.
Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67(2):316–20.
Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521.
van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam. J Natl Cancer Inst. 2003;95(19):1462–6.
Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam. J Natl Cancer Inst. 2007;99(17):1296–303.
Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.
Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.
Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC). Eur Urol. 2009;56(4):584–91.
Aus G, Bergdahl S, Lodding P, et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer – results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51:659–64.
Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725–32.
Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46–52.
Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325(7367):740.
Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut: fifteen year follow-up. J Gen Intern Med. 2008;23(11):1809–14.
Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717–23; discussion 724.
Ljung BM, Cherrie R, Kaufman JJ. Fine needle aspiration biopsy of the prostate gland: a study of 103 cases with histological follow up. J Urol. 1986;135(5):955–8.
Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311–8.
Oberaigner W, Horninger W, Klocker H, et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164(4):376–84.
Cochrane AL. 1931–1971: a critical review, with particular reference to the medical profession. In: Medicines for the year 2000. London: Office of Health Economics; 1979. p. 1–11.
Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:CD004720.
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. Prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981–90.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9.
Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83.
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst. 2003;95(12):868–78.
Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.
Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85.
Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology. 2006;68(6):1152–5.
Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–8.
Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30(2):181–4.
Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1–12.
Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011;107(1):28–39.
Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet. 2009;10(2):77–82.
Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–21.
Whitaker HC, Kote-Jarai Z, Ross-Adams H, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010;5(10):e13363. doi:10.1371/journal.pone.0013363.
Lin K, Croswell JM, Koenig HC, Lam C, Maltz A. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Yates, D.R., Anderson, J.B. (2013). Screening for Prostate Cancer. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_27
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2864-9_27
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2863-2
Online ISBN: 978-1-4471-2864-9
eBook Packages: MedicineMedicine (R0)